E2MATE For Treating Endometriosis

Risk of prostate cancer in two age groups based on Free PSA as % of Total PSA Catalona W, Partin A, Slawin K, Brawer M, Flanigan R, Patel A, Richie J, deKernion J, Walsh P, Scardino P, Lange P, Subong E, Parson R, Gasior G, Loveland K, Southwick P (1998). “Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial”. JAMA 279 (19) : 1542–7. doi:10.1001/jama.279.19.1542. PMID 9605898. (Photo credit: Wikipedia)

Endometriosis is a gynecological disorder. Tens of millions around the world suffer from this painful ailment where there is an overgrowth in the lining of the uterus, the endometrium.

A drug has been tested at the University of Bath. It has passed the critical clinical trial and it looks promising. This drug, E2MATE (PGL2001), is a product of the Medicinal Chemistry Group at the Pharmacy and Pharmacology Department of the University. It has been used in Phase 2 cancer treatments before. But it now seems to be useful for treating the non-cancerous Endometriosis.

Following the E2MATE’s promising clinical trial, the research is now on a 2008 paper published from the efforts of the University of Bath and London’s Imperial College. The drug they looked at is called Irosustat.

Professor Barry Potter headed up the two research teams. He is pleased with the results that all their hard work yielded. He notes that only a few drugs investigated as new treatments show promising results in their trials. But with E2MATE, he can see the drug going far.

Preglem, a pharmaceutical company, conducted the trials but Sterix Ltd., co-founded by Potter, owns the formulation and the study behind E2MATE. An overview of the research about Endometriosis Treatment appeared in the Reproductive Sciences journal.

New Treatment For Endometriosis Investigated

A new drug promising to be useful in treatment of the gynecological disorder known as Endometriosis has passed a critical clinical trial at the University of Bath. A specific product of the Medicinal Chemistry Group at the University’s Pharmacy and Pharmacology Department, the drug E2MATE (or PGL2001) is used in Phase 2 cancer treatment, but also appears useful for this the non-cancerous Endometriosis.

Across the globe, tens of millions of women suffer from the pain and infertility that the overgrowth of their endometrium (lining of the uterus) causes. Current Endometriosis Treatment does not seem effective and have unwanted side effects.

Regarding the now promising clinical trial of E2MATE, the research stands on a 2008 published paper from the combined efforts London’s Imperial College and the University at Bath. They looked at a drug called Irosustat.

Professor Barry Potter, who headed up both research teams, is pleased with the results of their work. He indicated that few drugs which are investigated as new treatments make it to the point where their trials show promise. Many trials halt as large budgets and extensive work and cooperation among scientists are just not there. Furthermore, he said he could see the scientific ideas and the drug going forward to treat this difficult gynecological condition. The obstacles were huge, but how E2MATE should be ready for use on women.

The pharmaceutical company Preglem conducted the trials. Sterix Ltd., co-founded by Professor Potter, owns the research and formulation behind E2MATE. Ipsen acquired the company in 2004. An overview of the study on Endometriosis Treatment was published in the Reproductive Sciences journal.